Leishmaniasis Clinical Trial
Official title:
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates LEISH-F3 + GLA-SE, LEISH-F3 + MPL-SE, and LEISH-F3 + SE in Healthy Adult Subjects
Investigational products: LEISH-F3 (recombinant protein antigen) + GLA-SE (adjuvant) leishmaniasis vaccine and LEISH-F3 (recombinant protein antigen) + MPL-SE (adjuvant) leishmaniasis vaccine. Stage of development: Phase 1 clinical development. Healthy adult subjects, 18 to 49 will be recruited through a U.S. site. Primary objective: To evaluate the safety and tolerability of the LEISH-F3 + GLA-SE vaccine and the LEISH-F3 + MPL-SE vaccine following intramuscular (IM) administration of 20 µg of LEISH-F3 together with 2 or 5 µg of GLA-SE or 10 µg of MPL-SE on Days 0, 28, and 168. Secondary objective: To assess the immunogenicity of LEISH-F3 formulated with GLA-SE, MPL-SE, or SE by evaluating IgG antibody responses to LEISH-F3 at Days 0, 28, 56, 168, 196, and 365, and T cell responses to LEISH-F3 at Days 0, 14, 42, 168, 182, and 365. Each subject's duration of participation will be about 18 months.
Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania. The parasites are transmitted from an animal or human reservoir through the bite of infected female phlebotomine sand flies. This study is a randomized, open-label clinical trial designed to evaluate the safety, tolerability, and immunogenicity of the LEISH-F3 recombinant protein antigen formulated with GLA-SE, MPL-SE, or SE adjuvant in healthy adults 18 to 49 years of age. Each subject's duration of participation will be about 18 months. Subjects will receive a total of 3 doses of vaccine, which will be given by intramuscular injection on Days 0, 28, and 168. The volume of each vaccine dose will be 0.5 mL. A computerized system will be used to acquire any data regarding halting criteria throughout the study. Primary objective is to evaluate the safety and tolerability of LEISH-F3 formulated with GLA-SE, MPL-SE, or SE following intramuscular administration of 20 µg of LEISH-F3 together with 5 µg of GLA-SE, 10 µg of MPL-SE, or SE alone. Secondary objective is to assess the immunogenicity of LEISH-F3 formulated with GLA-SE, MPL-SE, or SE by evaluating IgG antibody responses to LEISH-F3 at Days 0, 28, 56, 168, 196, and 365, and T cell responses to LEISH-F3 at Days 0, 14, 42, 168, 182, and 365. A substudy will be performed using up to 12 subjects from each Study Group (Groups 1, 2 and 3) and an additional 12 subjects to serve as controls. This substudy will investigate whether, as in murine cells, cell surface markers (CD11a, CD49d) can be used as a surrogate to identify protective immune CD4+ T cells in human subjects receiving a vaccine antigen. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT04504435 -
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
|
Phase 1 | |
Completed |
NCT00004755 -
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
|
Phase 2 | |
Completed |
NCT00657618 -
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
|
Phase 1/Phase 2 | |
Completed |
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A | |
Recruiting |
NCT00344188 -
Diagnosis and Treatment of Leishmania Infections
|
||
Active, not recruiting |
NCT03009422 -
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
|
N/A | |
Recruiting |
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
||
Recruiting |
NCT06307171 -
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
|
N/A | |
Terminated |
NCT06124144 -
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
|
Phase 1 | |
Completed |
NCT00662012 -
Sodium Stibogluconate Treatment of Leishmaniasis
|
Phase 2 | |
Completed |
NCT03993093 -
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
|
||
Recruiting |
NCT03784248 -
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
|
||
Withdrawn |
NCT02429505 -
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|
||
Completed |
NCT01377974 -
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
|
Phase 2 | |
Completed |
NCT02656797 -
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT01484548 -
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT01300975 -
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
Completed |
NCT00401349 -
Expression of Mif Alleles in Individuals With Leishmaniasis
|